A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors

PURPOSE: This study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the intravenous pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors. EXPERIMENTAL DESIGN: In Part 1, patients received escalating doses of danusertib...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cohen, Roger B., Jones, Suzanne F., Aggarwal, Charu, von Mehren, Margaret, Cheng, Jonathan, Spigel, David R., Greco, F. Anthony, Mariani, Mariangela, Rocchetti, Maurizio, Ceruti, Roberta, Comis, Silvia, Laffranchi, Bernard, Moll, Jurgen, Burris, Howard A.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2009
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826106/
https://ncbi.nlm.nih.gov/pubmed/19825950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1445
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים